Ambrx Overview
- Year Founded
-
2003
- Status
-
Acquired/Merged
- Employees
-
66
- Latest Deal Type
-
M&A
- Financing Rounds
-
15
Ambrx General Information
Description
Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.
Contact Information
Website
www.ambrx.com(Operating Subsidiary)
Corporate Office
- 10975 North Torrey Pines Road
- La Jolla
- San Diego, CA 92037
- United States
Corporate Office
- 10975 North Torrey Pines Road
- La Jolla
- San Diego, CA 92037
- United States
Ambrx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ambrx Comparisons
Industry
Financing
Details
Ambrx Competitors (52)
One of Ambrx’s 52 competitors is Byondis, a Corporation company based in Nijmegen, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Byondis | Corporation | Nijmegen, Netherlands | ||||
| aTyr Pharma | Formerly VC-backed | San Diego, CA | ||||
| Transgene | Corporation | Illkirch-Graffenstaden, France | ||||
| Mersana Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Inhibrx | Formerly VC-backed | La Jolla, CA |
Ambrx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ambrx Patents
Ambrx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024329469-A1 | Anti-psma adc conjugate compositions and methods of use thereof | Pending | 22-Aug-2023 | ||
| EP-4766404-A1 | Anti-psma adc conjugate compositions and methods of use thereof | Pending | 22-Aug-2023 | ||
| WO-2025041055-A1 | Anti-psma adc conjugate compositions and methods of use thereof | Inactive | 22-Aug-2023 | ||
| WO-2024241086-A1 | Pegylated bovine interferon lambda and methods of use thereof | Inactive | 24-May-2023 | ||
| WO-2024215515-A1 | Drug linkers and antibody conjugates thereof | Inactive | 14-Apr-2023 | C07D491/22 |
Ambrx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ambrx Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Ambrx FAQs
-
When was Ambrx founded?
Ambrx was founded in 2003.
-
Where is Ambrx headquartered?
Ambrx is headquartered in San Diego, CA.
-
What is the size of Ambrx?
Ambrx has 66 total employees.
-
What industry is Ambrx in?
Ambrx’s primary industry is Drug Discovery.
-
Is Ambrx a private or public company?
Ambrx is a Private company.
-
What is the current valuation of Ambrx?
The current valuation of Ambrx is .
-
What is Ambrx’s current revenue?
The current revenue for Ambrx is .
-
How much funding has Ambrx raised over time?
Ambrx has raised $524M.
-
Who are Ambrx’s investors?
5AM Ventures, Adage Capital Management, Alexandria Venture Investments, Apposite Capital, and Apricot Capital are 5 of 34 investors who have invested in Ambrx.
-
Who are Ambrx’s competitors?
Byondis, aTyr Pharma, Transgene, Mersana Therapeutics, and Inhibrx are some of the 52 competitors of Ambrx.
-
When was Ambrx acquired?
Ambrx was acquired on 07-Mar-2024.
-
Who acquired Ambrx?
Ambrx was acquired by Johnson & Johnson.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
